PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL

Patients 65 and older with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with a chemotherapy-free combination had excellent median overall survival and disease-free survival times, confirming benefits of this regimen are durable

2023-12-09
(Press-News.org)

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab. 

These long-term results from the S1318 clinical trial will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego on December 9 (abstract 1499).

Anjali S. Advani, MD, a SWOG investigator at Cleveland Clinic Cancer Institute, led the study, with study co-chair Kristen O’Dwyer, MD, of the Wilmot Cancer Institute at the University of Rochester.

“These long-term results are encouraging and suggest that this regimen is an active regimen for the treatment of older patients with Ph+ ALL,” said Dr. Advani, who will present the findings at the ASH meeting.

Treatment for Ph+ ALL typically includes tyrosine kinase inhibitors (TKIs) and intensive chemotherapy, but many patients age 65 or older cannot tolerate the side effects of the chemotherapy and are treated with TKIs plus corticosteroids. Median disease-free survival (DFS) times with this approach, however, have been short. More effective treatment regimens with less toxicity are needed.

The S1318 clinical trial, led by the SWOG Cancer Research Network, a clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), tested a combination treatment for these Ph+ patients that added immunotherapy with blinatumomab (a bispecific T-cell engager) to dasatinib (a TKI) and prednisone (a corticosteroid). 

Initial S1318 results in Ph+ patients were presented at the 2021 ASH meeting and demonstrated that the combination was well tolerated by these patients and was efficacious, with a high rate of complete remission and promising estimates for three-year OS and DFS. But longer follow-up was needed to learn whether the benefit would be durable. 

The current ASH abstract presents long-term S1318 results in Ph+ patients, confirming the durability of the initial benefit. The median OS is 6.5 years, and with a median follow-up time of 4.3 years, median DFS had not yet been reached as of mid-2023.

The 24 eligible patients with Ph+ ALL on S1318 were all newly diagnosed with the disease. All received initial induction therapy with dasatinib and prednisone. If their disease did not go into complete remission, they received re-induction therapy with blinatumomab. Post-remission therapy consisted of blinatumomab and dasatinib, and maintenance therapy included prednisone and dasatinib.

Twenty-two of the 24 patients saw a complete remission (CR) of their disease on the combination treatment. Measurements of minimal residual disease (MRD), taken at day 28 of treatment, were available for 16 of those 22 patients. Six of these 16 patients (38%) were found to show no evidence of MRD at day 28.

Two patients experienced treatment-related non-hematologic Grade 4 toxicities during induction therapy, but no patients experienced Grade 4 or higher treatment-related non-hematologic toxicities during post-remission or maintenance therapy.
 

Study S1318 is sponsored by the NCI, led by SWOG, and conducted by the NIH-funded National Clinical Trials Network (NCTN).

The study is funded by the NIH/NCI through grants CA180888, CA180819, CA180820, and CA180821. Bristol Myers Squibb and Amgen Inc. provided support for S1318 through Cooperative Research and Development Agreements with NCI.

In addition to Drs. Advani and O’Dwyer, co-authors on this work include Anna Moseley, MS, SWOG Statistics and Data Management Center and Fred Hutchinson Cancer Center; Brent L. Wood, MD, PhD, University of Washington (during trial) and Children’s Hospital Los Angeles (current); Jae Park, MD, Memorial Sloan Kettering Cancer Center; Matthew Wieduwilt, MD, University of California San Diego Moores Cancer Center (during trial) and University of Oklahoma (current); Deepa Jeyakumar, MD, UC Irvine Medical Center; George Yaghmour, MD, USC Norris Comprehensive Cancer Center; Ehab L. Atallah, MD, Froedtert and the Medical College of Wisconsin; Aaron T. Gerds, MD, MS, Cleveland Clinic Cancer Institute; Susan M. O'Brien, MD, UC Irvine Medical Center; Jane L. Liesveld, MD, University of Rochester; Megan Othus, PhD, SWOG Statistics and Data Management Center and Fred Hutchinson Cancer Center; Mark Litzow, MD, Mayo Clinic, Rochester; Richard M. Stone, MD, Dana-Farber Cancer Institute; Elad Sharon, MD, MPH, NCI Cancer Therapy Evaluation Program (CTEP); Cecilia C.S. Yeung, MD, Fred Hutchinson Cancer Center; Jerald P. Radich, MD, Fred Hutchinson Cancer Center; and Harry P. Erba, MD, PhD, Duke University Medical Center.
 

SWOG Cancer Research Network is part of the National Cancer Institute's National Clinical Trials Network and the NCI Community Oncology Research Program and is part of the oldest and largest publicly funded cancer research network in the nation. SWOG has 20,000 members in 45 states and nine other countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at swog.org, and follow us on Twitter (X) at @SWOG.
 

Reference:
Advani AS et al. “Long-term Follow for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL).” 
Poster Session: 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I 
Session Date: Saturday, December 9, 2023 
Presentation Time: 5:30 PM - 7:30 PM, PT
Location: San Diego Convention Center, Halls G-H

END



ELSE PRESS RELEASES FROM THIS DATE:

Mindfulness could help women with opioid use disorder better control drug urges

2023-12-09
Mindfulness-Oriented Recovery Enhancement (MORE) — a behavioral intervention that integrates training in mindfulness, emotion regulation strategies and savoring of natural rewards — could hold the key to mitigating relapse in women undergoing medically assisted opioid use disorder treatment, a Rutgers study found.   The pilot study published in the journal Explore, is the first to evaluate the potential neural changes that underlie women’s emotion regulation and craving after an eight-week MORE intervention.   Previous studies have shown that women report higher opioid craving and show a greater inability to ...

TTUHSC’s ARPA-H membership will spur innovation, improve access for West Texas patients

TTUHSC’s ARPA-H membership will spur innovation, improve access for West Texas patients
2023-12-09
Imagine if scientists developed a customizable cancer vaccine that was available — and affordable — for everyone. What if a patient scheduled for surgery also had the option of taking a pill whose composition includes nanorobotics capable of performing the procedure? These and other medical scenarios may seem far-fetched and better suited to a science fiction thriller. However, the Advanced Research Projects Agency for Health (ARPA-H) is seeking to take such ideas from the drawing board to ...

Global annual finance flows of $7 trillion fueling climate, biodiversity, and land degradation crises

2023-12-09
Almost US$7 trillion per year in government subsidies and private investment - around 7 per cent of global GDP - has a direct negative impact on nature. Nature-based solutions remain dramatically underfunded. Current public and private finance flows are only US$200 billion per year. To meet climate, biodiversity, and restoration targets, this needs to triple by 2030 and quadruple by 2050. Realignment of public and private nature-negative finance flows is urgently needed Dubai, 9 December 2022 – Close to $7 trillion is invested globally each year in activities that have a direct negative impact on nature from both public and private sector sources - equivalent to ...

Tracing how the infant brain responds to touch with near-infrared spectroscopy

Tracing how the infant brain responds to touch with near-infrared spectroscopy
2023-12-09
Tokyo, Japan – Researchers from Tokyo Metropolitan University have measured how oxygenated hemoglobin levels in the blood change in infants’ brains in response to touch. Using spectroscopy methods with external sensors placed on the scalp of sleeping infants, they found that the time at which levels peak doesn’t change with infant age, but the amount by which it varies over time does. Insights like this shed light on how the physiology of infants develop. The first phase of a newborn’s life is a dazzling array of rapid developmental ...

These are the world's most effective charities

2023-12-09
Which charities will be most effective in ensuring your donation is put to good use? For the first time in the Netherlands, researchers applied scientific methods to pinpoint which charities achieve the most with the donations they receive. The University of Amsterdam and Stichting Doneer Effectief (Donate Effectively Foundation) unveiled the list on Friday, 8 December, during a sold out evening in Rotterdam. ‘We are talking about the Champions League of good causes,’ says professor of Philanthropy & Sustainable Investment Paul Smeets of the University of Amsterdam. The ranking ...

When is an aurora not an aurora?

When is an aurora not an aurora?
2023-12-08
The shimmering green, red and purple curtains of the northern and southern lights — the auroras — may be the best-known phenomena lighting up the nighttime sky, but the most mysterious are the mauve and white streaks called Steve and their frequent companion, a glowing green "picket fence." First recognized in 2018 as distinct from the common auroras, Steve — a tongue-in-cheek reference to the benign name given a scary hedge in a 2006 children's movie — and its associated picket fence were nevertheless thought to be caused by the same physical processes. But scientists were left scratching their heads about how these glowing emissions ...

Advisory panel issues field-defining recommendations for US government investments in particle physics research

2023-12-08
The High Energy Physics Advisory Panel (HEPAP) to the High Energy Physics program of the Office of Science of the U.S. Department of Energy and the National Science Foundation’s Division of Physics has released a new Particle Physics Project Prioritization Panel (P5) report, which outlines particle physicists’ recommendations for research priorities in a field whose projects — such as building new accelerator facilities — can take years or decades, contributions from thousands of scientists, and billions of dollars.  The 2023 P5 report represents the major activity in the field of particle physics that ...

Doctors discover many patients at UNC’s Inflammatory Bowel Disease Clinic screen positive for malnutrition

Doctors discover many patients at UNC’s Inflammatory Bowel Disease Clinic screen positive for malnutrition
2023-12-08
CHAPEL HILL, NC — Eating food and absorbing its nutrients is an everyday occurrence, but this normal activity can look different for someone who suffers from inflammatory bowel disease. IBD, which includes Crohn’s disease and ulcerative colitis, can cause chronic inflammation of the digestive tract – which for many reasons can lead to malnutrition. This malnourished state is associated with an increased risk of morbidity and mortality, and new findings show that many patients in IBD clinic screen positive for malnutrition, leading to the critical need for same-day ...

BNL: Advisory panel issues field-defining recommendations for U.S. government investments in particle physics research

2023-12-08
The following news release on the 2023 Particle Physics Project Prioritization Panel (P5) report is based on one issued today by the American Physical Society (APS) with added content specific to the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory. For more information about Brookhaven Lab’s research in particle physics, contact: Karen McNulty Walsh, kmcnulty@bnl.gov, (631) 344-8350. For APS media inquiries, contact Anna Torres, torres@aps.org, (301) 209-3605. WASHINGTON, ...

International collaboration uses faculty member’s research on ancient Roman migration, seeks to understand Balkan genomic history

International collaboration uses faculty member’s research on ancient Roman migration, seeks to understand Balkan genomic history
2023-12-08
STARKVILLE, Miss.––A Mississippi State University anthropologist’s bioarchaeological analysis and bone samples from ancient Roman burial sites were crucial in the development of new research regarding Roman and Balkan migration featured this week in Cell, a prestigious peer-reviewed journal. Anna Osterholtz, an associate professor in the Department of Anthropology and Middle Eastern Cultures, provided her research on the “lived experiences” of the Romans in Croatia. She currently works closely with museum ...

LAST 30 PRESS RELEASES:

Cells that die during inflammation send wound-healing messages 

Risk of secondary cancers after CAR T therapy may be similar to risk after other cancer treatments

Enhance and revise for better low-light image enhancement

Multiple ways to evolve tiny knee bone could have helped humans walk upright

UBCO study explores access to psychedelics for therapeutic use

Lower diligence level linked to higher cardiovascular disease risk in type 2 diabetes

Statins cost effective and linked to better health outcomes in older people

Abdominal fat linked to widespread chronic pain, especially in women

Wearable brain imaging device shines a light on how babies respond in real-world situations

"Cuddle hormone" oxytocin may provide pain relief and help curb harmful opioid use

Study reveals mechanism that activates glucose production in the liver in response to stress

Aumolertinib maintenance after chemoradiotherapy in stage III non-small cell lung cancer improves PFS compared to placebo

Weight loss of up to 13% achieved in three months with once-a-day tablet, phase 1 trial finds

Time-restricted eating improves blood sugar control in adults at risk of type 2 diabetes regardless of time of day

Individuals with complications of diabetes are at higher risk of gum disease, Danish study finds

Weight loss drug liraglutide is safe and effective in children under 12, study finds

Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

The glug of it all

UTA to build netted drone facility in Fort Worth

Streamlining energy regulations on Native American reservations could help alleviate poverty

UT microbiologist Wilhelm honored as Fellow of the Royal Society of Canada

NCCN Policy Summit explores how to build an inclusive cancer center workplace culture that better serves everybody

Games, puzzles and reading can slow cognitive decline in the elderly — even in those with mild cognitive impairment

An antidiabetic helps the immune system recognize reservoirs of HIV

Department of Energy grant advances clean energy studies

Finding the right path(way) to reduce fat accumulation in the liver

MicroDicer and MicroGrater make quick work of tumor dissection

Phase II study of taletrectinib shows clinically meaningful overall response and favorable safety in patients with ROS1+ non-small cell lung cancer

LUMINOSITY trial demonstrates telisotuzumab vedotin shows durable response in Asian patients with c-Met protein-overexpressing EGFR WT nonsquamous NSCLC

PM2.5 exposure may affect lung cancer in women who have never smoked

[Press-News.org] Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL
Patients 65 and older with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with a chemotherapy-free combination had excellent median overall survival and disease-free survival times, confirming benefits of this regimen are durable